Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialisation of innovative medicines for rare neuromuscular neuromuscular and pulmonary diseases with high unmet medical need, has announced an equity financing of CHF 20
Tags :Christian Leuenberger
Pestalozzi advises global institutional investors (“Investors”) in connection with an amendment to the up to $44,000,000 equity linked investment in WISeKey International Holding (“WISeKey”) listed at SIX Swiss Exchange and with ADS traded at NASDAQ, agreed
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
Pestalozzi advises global institutional investors in connection with up to $ 44,000,000 equity linked investment in WISeKey International Holding listed at SIX Swiss Exchange and with ADS traded at Nasdaq. The investment is structured in two convertible
The Pestalozzi team included Christian Leuenberger (Lead Partner - Capital Markets, Corporate/M&A - pictured), Severin Roelli (Partner - Corpoarte/M&A), Manu Ferro (Associate - Banking & Finance).
Pestalozzi advises Achiko in connection with convertible loan from Negma Group and the issuance of warrants. The team included Christian Leuenberger (Partner - Corporate / M&A, Capital Markets, pictured)
